Heavy marketing of krill oil has focused on the superior bioavailability of the phospholipid form of omega-3 over that of triglyceride omega-3 from fish oil. This appealing concept has been given disproportionate importance while the justifiably important factor of dose has been virtually ignored. Consumers have been misled into believing that taking low doses of EPA and DHA omega-3 from krill oil will provide health benefits comparable to those associated with larger doses of EPA and DHA from fish oil.
The evidence supporting the need for high doses of omega-3 fatty acids, and in particular EPA, in the treatment of a variety of health conditions, clearly demonstrates that manufacturer-recommended doses of krill oil capsules (approximately 300 mg) do not provide sufficient levels of EPA and DHA to increase blood levels of omega-3s and have no place in therapeutic, clinical nutrition where outcomes are dependent on raising the omega-3 index to a minimum 8%.
To achieve the same level of EPA and DHA in red blood cell membranes (an important health biomarker called the omega-3 index) you need approximately 40% more krill oil than fish oil. Since krill oil is already about 3x the price of standard fish oil for the same volume, it is considerably more expensive to achieve higher volumes of krill oil just to achieve the same omega-3 blood profile as produced by fish oil.
Read more about why krill oil is not a viable alternative to fish oil here>
← Why don’t you offer krill oil?